SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
iCo Therapeutics Inc. Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for $33 Million Plus Royalties